Background: In oestrogen- receptor positive breast cancer, daily oral adjuvant endocrine therapy (ET) for at least 5 years significantly reduces risks of recurrence and breast cancer- specific mortality. However, many women are poorly adherent to ET. Development of effective adherence support requires comprehensive understanding of influences on adherence. We undertook an umbrella review to identify determinants of ET adherence.Methods: We searched PubMed, Embase, CINAHL, PsycINFO, Cochrane and PROSPERO (inception to 08/2022) to identify systematic reviews on factors influencing ET adherence. Abstracted determinants were mapped to the World Health Organization's dimensions of adherence. Reviews were quality appraised and overlap assessed.Results: Of 5732 citations screened, 17 reviews were eligible (9 quantitative primary studies; 4 qualitative primary studies; 4 qualitative or quantitative studies) including 215 primary papers. All five WHO dimensions influenced ET non- adherence: The most consistently identified non- adherence determinants were patient- related factors (e.g. lower perceived ET necessity, more treatment concerns, perceptions of ET ‘cons’ vs. ‘pros’). Healthcare system/healthcare professional- related factors (e.g. perceived lower quality health professional interaction/relationship) were also important and, to a somewhat lesser extent, socio- economic factors (e.g. lower levels of social/economic/material support). Evidence was more mixed for medication- related and condition- related factors, but several may be relevant (e.g. experiencing side- effects, cost). Potentially modifiable factors are more influential than non- modifiable/fixed factors (e.g. patient characteristics).
Todd, AdamWaldron, CatherineMcGeagh, Lucy Norris, RuthBolnykh, IakovStewart, Sarah JaneSlodkowska- Barabasz, Joanna Moon, ZoeCahir, CaitrionaThompson, SueHarmer, VictoriaWells, MaryWatson, Eila Sharp, LindaSWEET Research Team
Department of Nursing
Year of publication: 2024Date of RADAR deposit: 2024-01-30